A pharmaceutical composition comprising (i) particles of Compound (5 I) in Form N-1 (ii) stabilizer； and (iii) at least one pharmaceutically acceptable carrier and / or diluent； wherein said particles have a diameter (D90) in the range of 1 to 50 micrometers and said stabilizer is arranged in said particles； wherein said stabilizer is a cellulose ether polymer； wherein said Form N-1 is characterized by one or more of the following: (a) a simulated powder X-ray diffraction pattern (PXRD) substantially equal to that shown in Figure 1, and / or an observed PXRD pattern substantially equal to that shown in Figure 1； b) a PXRD pattern comprising four or more values of 2q (CuK l>； = 1.5418 Å) chosen from: 6.2 ± 0.2； 7.7 ± 0.2； 11.0>； ± 0.2； 12.2 ± 0.2； 18.5 ± 0.2； 21.6 ± 0.2； 22.2 ± 0.2； and 23.0 ± 0.2, wherein the PXRD pattern of Form N-1 is measured at a temperature of approximately 25 ° C； c) a PXRD pattern comprising five or more values of 2q (CuK l>； = 1.5418 Å) chosen from: 6.2 ± 0.2； 7.7 ± 0.2； 11.0 ± 0.2； 12.2 ± 0.2； 18.5 ± 0.2； 21.6 ± 0.2； 22.2 ± 0.2； and 23.0 ± 0.2, in which the PXRD pattern of Form N-1 is measured at a temperature of approximately 25 ° C； d) unit cell parameters substantially equal to the following: Cell dimensions: a>； = 14.45 Å b>； = 19.21 Å c>； = 8.89 Å α>； = 90.0º β>； = 95, 7th γ>； = 90.0 ° Space group: P21 / c Molecules of Compound (I) / asymmetric unit: 1 where the unit cell parameters of Form N-1 are measured at a temperature of approximately 25 ° C； e) unit cell parameters substantially equal to the following: Cell dimensions: a>； = 14.43 Å b>； = 19.17 Å c>； = 8.83 Å α>； = 90.0º β>； = 95.4º γ>； = 90.0º Space group: P21 / c Molecules of Compound (I) / asymmetric unit: 1 where the unit cell parameters of Form N-1 are measured at a temperature of approximately -30 ° C； and / or f) a melting point in the range of from about 211 ° C to about 217 ° C.Una composición farmacéutica que comprende (i) partículas del C
